278 related articles for article (PubMed ID: 15756254)
1. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Schmitt E; Gertenbach U; Fornara P; Heynemann H; Maskow A; Ecke M; Wöltjen HH; Jentsch H; Wieland W; Wandert T; Reitz M;
Br J Cancer; 2005 Mar; 92(5):843-6. PubMed ID: 15756254
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
[TBL] [Abstract][Full Text] [Related]
4. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
5. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial.
Aitchison M; Bray CA; Van Poppel H; Sylvester R; Graham J; Innes C; McMahon L; Vasey PA
Eur J Cancer; 2014 Jan; 50(1):70-7. PubMed ID: 24074763
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
9. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2005 Aug; 20(4):410-6. PubMed ID: 16114989
[TBL] [Abstract][Full Text] [Related]
10. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
12. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.
Pizzocaro G; Piva L; Colavita M; Ferri S; Artusi R; Boracchi P; Parmiani G; Marubini E
J Clin Oncol; 2001 Jan; 19(2):425-31. PubMed ID: 11208835
[TBL] [Abstract][Full Text] [Related]
13. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
Atzpodien J; Hoffmann R; Franzke M; Stief C; Wandert T; Reitz M
Cancer; 2002 Sep; 95(5):1045-50. PubMed ID: 12209689
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
Doehn Ch; Richter A; Lehmacher W; Jocham D
Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
Messing EM; Manola J; Wilding G; Propert K; Fleischmann J; Crawford ED; Pontes JE; Hahn R; Trump D;
J Clin Oncol; 2003 Apr; 21(7):1214-22. PubMed ID: 12663707
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
[TBL] [Abstract][Full Text] [Related]
17. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
19. Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2006 Jun; 21(3):206-10. PubMed ID: 16918296
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
